How will insights from genetics translate to clinical practice in inflammatory bowel disease?

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 3, 2014, Pages 387-397

  Festen, E A M ^a   Weersma, R K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti TNF therapy; Crohn's disease; Drug repositioning; Genetics; Inflammatory bowel disease; Personalised medicine; Pharmacogenetics; Thiopurines; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMG 557; DENOSUMAB; EVEROLIMUS; INTERLEUKIN 12; INTERLEUKIN 23; JANUS KINASE; MONOCLONAL ANTIBODY; NATALIZUMAB; RAPAMYCIN; TOFACITINIB; TOPIRAMATE; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ARTICLE; AUTOPHAGY; CLINICAL PRACTICE; DISEASE COURSE; DRUG REPOSITIONING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE; PROGNOSIS; PROTEIN TARGETING; QUANTITATIVE TRAIT LOCUS; REMISSION;

ANTI-TNF THERAPY; CROHN'S DISEASE; DRUG REPOSITIONING; GENETICS; INFLAMMATORY BOWEL DISEASE; PERSONALISED MEDICINE; PHARMACOGENETICS; THIOPURINES; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS;

EID: 84902281714     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.04.002     Document Type: Review

References (86)

1. Finishing the euchromatic sequence of the human genome Nature 431 2004 931 945
2. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 2004 464 468
3. L. Jostins, S. Ripke, R.K. Weersma, R.H. Duerr, D.P. McGovern, and K.Y. Hui et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 491 2012 119 124
4. G. D'Haens, F. Baert, G. van Assche, P. Caenepeel, P. Vergauwe, and H. Tuynman et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 2008 660 667
5. K. Fransen, M. Mitrovic, C.C. van Diemen, and R.K. Weersma The quest for genetic risk factors for Crohn's disease in the post-GWAS era Genome Med 3 2011 13
6. R.M. Plenge, E.M. Scolnick, and D. Altshuler Validating therapeutic targets through human genetics Nat Rev Drug Discov 12 2013 581 594
7. S. Kathiresan, O. Melander, C. Guiducci, A. Surti, N.P. Burtt, and M.J. Rieder et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans Nat Genet 40 2008 189 197
8. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II JAMA 256 1986 2829 2834
9. E.J. Rossin, K. Lage, S. Raychaudhuri, R.J. Xavier, D. Tatar, and Y. Benita et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology PLoS Genet 7 2011 e1001273
10. R.H. Duerr, K.D. Taylor, S.R. Brant, J.D. Rioux, M.S. Silverberg, and M.J. Daly et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Science 314 2006 1461 1463
11. M. Reddy, C. Davis, J. Wong, P. Marsters, C. Pendley, and U. Prabhakar Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275 Cell Immunol 247 2007 1 11
12. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, and S. Katz et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
13. W.J. Sandborn, C. Gasink, L.-L. Gao, M.A. Blank, J. Johanns, and C. Guzzo et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 2012 1519 1528
14. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, C. Su, and S. Rousell et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N Engl J Med 367 2012 616 624
15. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, W. Wang, and W. Niezychowski A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn's disease Clin Gastroenterol Hepatol 2014
16. S. Thomas, and D.C. Baumgart Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis Inflammopharmacology 20 2012 1 18
17. H.S. Souza, C.C. Elia, J. Spencer, and T.T. MacDonald Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease Gut 45 1999 856 863
18. S. Arihiro, H. Ohtani, M. Suzuki, M. Murata, C. Ejima, and M. Oki et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease Pathol Int 52 2002 367 374
19. H.-J. Westra, D. Arends, T. Esko, M.J. Peters, C. Schurmann, and K. Schramm et al. Cell specific eQTL analysis without sorting cells Cold Spring Harb Labs Journals 2014
20. B.G. Feagan, G.R. Greenberg, G. Wild, R.N. Fedorak, P. Paré, and J.W.D. McDonald et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin Clin Gastroenterol Hepatol 6 2008 1370 1377
21. B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J.-F. Colombel, and W.J. Sandborn et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
22. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, S. Hanauer, J.-F. Colombel, and B.E. Sands et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
23. A. Sakuraba, M.L. Annunziata, R.D. Cohen, S.B. Hanauer, and D.T. Rubin Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease Inflamm Bowel Dis 19 2013 2577 2583
24. S.M. Govani, A.K. Waljee, and P.D.R. Higgins Anti-adhesion therapies and the rule of 3 for rare events Am J Gastroenterol 108 2013 1831 1832
25. D.C.O. Massey, F. Bredin, and M. Parkes Use of sirolimus (rapamycin) to treat refractory Crohn's disease Gut 57 2008 1294 1296
26. W. Reinisch, J. Panés, M. Lémann, S. Schreiber, B. Feagan, and S. Schmidt et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease Am J Gastroenterol 103 2008 2284 2292
27. Y. Okada, D. Wu, G. Trynka, T. Raj, C. Terao, and K. Ikari et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature 2013
28. P.M. Clark, N. Dawany, W. Dampier, S.W. Byers, R.G. Pestell, and A. Tozeren Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases Inflamm Bowel Dis 18 2012 2315 2333
29. Y. Fukuoka, D. Takei, and H. Ogawa A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs Bioinformation 9 2013 89 93
30. P. Sanseau, P. Agarwal, M.R. Barnes, T. Pastinen, J.B. Richards, and L.R. Cardon et al. Use of genome-wide association studies for drug repositioning Nat Biotechnol 30 2012 317 320
31. J.T. Dudley, M. Sirota, M. Shenoy, R.K. Pai, S. Roedder, and A.P. Chiang et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease Sci Transl Med 3 2011 96ra76
32. S.D. Crockett, R. Schectman, T. Stürmer, and M.D. Kappelman Topiramate use does not reduce flares of inflammatory bowel disease Dig Dis Sci 2014
33. A. Franke, D.P.B. McGovern, J.C. Barrett, K. Wang, G.L. Radford-Smith, and T. Ahmad et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Nat Genet 42 2010 1118 1125
34. K.D. Häusler, N.J. Horwood, Y. Chuman, J.L. Fisher, J. Ellis, and T.J. Martin et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation J Bone Min Res 19 2004 1873 1881
35. H. Tilg, A.R. Moschen, A. Kaser, A. Pines, and I. Dotan Gut, inflammation and osteoporosis: basic and clinical concepts Gut 57 2008 684 694
36. C. Tysk, E. Lindberg, G. Järnerot, and B. Flodérus-Myrhed Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking Gut 29 1988 990 996
37. R.K. Weersma, P.C.F. Stokkers, A.A. van Bodegraven, R.A. van Hogezand, H.W. Verspaget, and D.J. de Jong et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort Gut 58 2009 388 395
38. E.A.M. Festen, P.C.F. Stokkers, C.C. van Diemen, A.A. van Bodegraven, H.M. Boezen, and B.J.A. Crusius et al. Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk Am J Gastroenterol 105 2010 395 402
39. A.D. Tyler, R. Milgrom, J.M. Stempak, W. Xu, J.H. Brumell, and A.M. Muise et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis Gut 62 2013 1433 1439
40. M.T. Abreu, K.D. Taylor, Y.-C. Lin, T. Hang, J. Gaiennie, and C.J. Landers et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease Gastroenterology 123 2002 679 688
41. J. Hampe, J. Grebe, S. Nikolaus, C. Solberg, P.J.P. Croucher, and S. Mascheretti et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study Lancet 359 2002 1661 1665
42. A.P. Cuthbert, S.A. Fisher, M.M. Mirza, K. King, J. Hampe, and P.J.P. Croucher et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease Gastroenterology 122 2002 867 874
43. T. Ahmad, A. Armuzzi, M. Bunce, K. Mulcahy-Hawes, S.E. Marshall, and T.R. Orchard et al. The molecular classification of the clinical manifestations of Crohn's disease Gastroenterology 122 2002 854 866
44. L. Henckaerts, K. Van Steen, I. Verstreken, I. Cleynen, A. Franke, and S. Schreiber et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients Clin Gastroenterol Hepatol 7 2009 972 980.e2
45. J. Seiderer, S. Brand, K.A. Herrmann, F. Schnitzler, R. Hatz, and A. Crispin et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study Inflamm Bowel Dis 12 2006 1114 1121
46. I. Cleynen, J.R. González, C. Figueroa, A. Franke, D. McGovern, and M. Bortlík et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project Gut 62 2013 1556 1565
47. J.A. Cavanaugh, K.E. Adams, E.J. Quak, M.E. Bryce, N.J. O'Callaghan, and H.J. Rodgers et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population Ann Hum Genet 67 2003 35 41
48. N.J. Prescott, S.A. Fisher, A. Franke, J. Hampe, C.M. Onnie, and D. Soars et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5 Gastroenterology 132 2007 1665 1671
49. J. Glas, A. Konrad, S. Schmechel, J. Dambacher, J. Seiderer, and F. Schroff et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population Am J Gastroenterol 103 2008 682 691
50. R.L. Roberts, R.B. Gearry, J.E. Hollis-Moffatt, A.L. Miller, J. Reid, and V. Abkevich et al. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease Am J Gastroenterol 102 2007 2754 2761
51. J.C. Lee, M. Espéli, C.A. Anderson, M.A. Linterman, J.M. Pocock, and N.J. Williams et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway Cell 155 2013 57 69
52. D.P. McGovern Characterization of the approximately 40,000 patient cohort of the international inflammatory bowel disease (IBD) genetics consortium (IIBDGC) Gastroenterology 144 2013 S-177
53. E. Hoefkens, K. Nys, J.M. John, K. Van Steen, I. Arijs, and J. Van der Goten et al. Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress Autophagy 9 2013 2046 2055
54. J.D. Ryan, M.S. Silverberg, W. Xu, L.A. Graff, L.E. Targownik, and J.R. Walker et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort Aliment Pharmacol Ther 38 2013 274 283
55. T. Montero-Meléndez, X. Llor, E. García-Planella, M. Perretti, and A. Suárez Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling PLoS One 8 2013 e76235
56. Z. Wei, W. Wang, J. Bradfield, J. Li, C. Cardinale, and E. Frackelton et al. Large sample size, wide variant spectrum, and advanced machine-learning technique boost risk prediction for inflammatory bowel disease Am J Hum Genet 92 2013 1008 1012
57. S.H. Lee, M.E. Goddard, N.R. Wray, and P.M. Visscher A better coefficient of determination for genetic profile analysis Genet Epidemiol 36 2012 214 224
58. J.K. Hou, B. Abraham, and H. El-Serag Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature Am J Gastroenterol 106 2011 563 573
59. J.K. Hou, D. Lee, and J. Lewis Diet and inflammatory bowel disease: review of patient-targeted recommendations Clin Gastroenterol Hepatol 2013
60. V. Andersen, A. Olsen, F. Carbonnel, A. Tjønneland, and U. Vogel Diet and risk of inflammatory bowel disease Dig Liver Dis 44 2012 185 194
61. P.L. Lakatos Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 27 2009 215 225
62. S.S. Mahid, K.S. Minor, R.E. Soto, C.A. Hornung, and S. Galandiuk Smoking and inflammatory bowel disease: a meta-analysis Mayo Clin Proc 81 2006 1462 1471
63. G. Koukos, C. Polytarchou, J.L. Kaplan, A. Morley-Fletcher, B. Gras-Miralles, and E. Kokkotou et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis Gastroenterology 145 2013 842 852.e2
64. A.-L. Barabási, N. Gulbahce, and J. Loscalzo Network medicine: a network-based approach to human disease Nat Rev Genet 12 2011 56 68
65. H.T.T. Nguyen, G. Dalmasso, S. Müller, J. Carrière, F. Seibold, and A. Darfeuille-Michaud Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy Gastroenterology 146 2014 508 519
66. S. Greenblum, P.J. Turnbaugh, and E. Borenstein Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease Proc Natl Acad Sci U. S. A 109 2012 594 599
67. X.C. Morgan, T.L. Tickle, H. Sokol, D. Gevers, K.L. Devaney, and D.V. Ward et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment Genome Biol 13 2012 R79
68. J. Jansson, B. Willing, M. Lucio, A. Fekete, J. Dicksved, and J. Halfvarson et al. Metabolomics reveals metabolic biomarkers of Crohn's disease PLoS One 4 2009 e6386
69. B.P. Willing, J. Dicksved, J. Halfvarson, A.F. Andersson, M. Lucio, and Z. Zheng et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes Gastroenterology 139 2010 1844 1854.e1
70. A.K. Daly, P.T. Donaldson, P. Bhatnagar, Y. Shen, I. Pe'er, and A. Floratos et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 41 2009 816 819
71. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, and F. Matsuda et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
72. M.K. Pasanen, H. Fredrikson, P.J. Neuvonen, and M. Niemi Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 82 2007 726 733
73. D. Voora, S.H. Shah, I. Spasojevic, S. Ali, C.R. Reed, and B.A. Salisbury et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
74. L. Becquemont, A. Alfirevic, U. Amstutz, H. Brauch, E. Jacqz-Aigrain, and P. Laurent-Puig et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on pharmacogenetics and pharmacogenomics Pharmacogenomics 12 2011 113 124
75. J.F. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J.P. Gendre, and B. Bonaz et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
76. L. Chisick, C. Oleschuk, and C.N. Bernstein The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease Can J Gastroenterol 27 2013 39 43
77. J.M. Van Dieren, B.E. Hansen, E.J. Kuipers, E.E.S. Nieuwenhuis, and C.J. Van der Woude Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease Aliment Pharmacol Ther 26 2007 643 652
78. G. Stocco, S. Martelossi, A. Barabino, G. Decorti, F. Bartoli, and M. Montico et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease Inflamm Bowel Dis 13 2007 57 64
79. D.R. Wong, L.J.J. Derijks, M.O. den Dulk, E.H.K.M. Gemmeke, and P.M. Hooymans The role of xanthine oxidase in thiopurine metabolism: a case report Ther Drug Monit 29 2007 845 848
80. M. Kudo, T. Moteki, T. Sasaki, Y. Konno, S. Ujiie, and A. Onose et al. Functional characterization of human xanthine oxidase allelic variants Pharmacogenet Genomics 18 2008 243 251
81. M.A. Smith, A.M. Marinaki, M. Arenas, M. Shobowale-Bakre, C.M. Lewis, and A. Ansari et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease Aliment Pharmacol Ther 30 2009 375 384
82. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W.J. Sandborn, and J.-F. Colombel Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 2008 644 653
83. W.J. Sandborn, S.B. Hanauer, P. Rutgeerts, R.N. Fedorak, M. Lukas, and D.G. MacIntosh et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
84. M. Pierik, S. Vermeire, K.V. Steen, S. Joossens, G. Claessens, and R. Vlietinck et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab Aliment Pharmacol Ther 20 2004 303 310
85. L.M. Medrano, C. Taxonera, A. Márquez, M. Barreiro-de Acosta, M. Gómez-García, and C. González-Artacho et al. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab Hum Immunol 75 2014 71 75
86. C. Steenholdt, C. Enevold, M.A. Ainsworth, J. Brynskov, O. Thomsen, and K. Bendtzen Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease Aliment Pharmacol Ther 36 2012 650 659